Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive ...
The FDA has accepted a resubmitted biologics license application (BLA) for tabelecleucel (tab-cel; Ebvallo), with a proposed ...
Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration ...
Practical guidance for starting belantamab: confirm eligibility, coordinate ophthalmology exams, manage reversible eye ...
Experts explain how myeloma regimens manage eye toxicity with baseline exams, dose holds, reductions, and longer belantamab ...
Industry payments to oncologists were associated with increased use of the promoted cancer treatment, regardless of whether ...
Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.
The phase 2 EVITA trial (NCT03682029) was the first double-blind, randomized, placebo-controlled study of oral vitamin C in ...
Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute rejects the idea that a TP53 co-mutation points toward chemotherapy ...
The investigational radiopharmaceutical therapy RYZ101 (225Ac-DOTATATE) produced a statistically significant and clinically ...
The NCCN published its first guidelines for pediatric bone sarcoma, centering on Ewing sarcoma and other undifferentiated ...
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results